http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 10 Sep 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Sep+08++Filed+by%3A+Opaleye+Management+Inc./27048376.html si-local-file:///var/storage/secattach/20260910/27048376.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Sep+08++Filed+by%3A+Opaleye+Management+Inc./27048376.html Thu, 10 Sep 2026 16:05:00 -0400 GRCE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Sep+09++Filed+by%3A+Kohli+Prashant/27045153.html si-local-file:///var/storage/secattach/20260910/27045153.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Sep+09++Filed+by%3A+Kohli+Prashant/27045153.html Thu, 10 Sep 2026 07:31:00 -0400 GRCE http://www.streetinsider.com/Equity+Offerings/Grace+Therapeutics+%28GRCE%29+files+for+4.76M+share+offering+by+selling+stockholders/26968152.html <p>Grace Therapeutics (NASDAQ: GRCE) filed for up to 4,761,904 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Grace+Therapeutics+%28GRCE%29+files+for+4.76M+share+offering+by+selling+stockholders/26968152.html Mon, 24 Aug 2026 16:08:16 -0400 GRCE http://www.streetinsider.com/Corporate+News/Grace+Therapeutics+%28GRCE%29+files+for+4.76M+share+offering+by+selling+stockholders/26968152.html <p>Grace Therapeutics (NASDAQ: GRCE) filed for up to 4,761,904 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Grace+Therapeutics+%28GRCE%29+files+for+4.76M+share+offering+by+selling+stockholders/26968152.html Mon, 24 Aug 2026 16:08:16 -0400 GRCE http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Grace+Therapeutics%2C+Inc.+++++++++++++/26968132.html si-local-file:///var/storage/secattach/20260824/26968132.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Grace+Therapeutics%2C+Inc.+++++++++++++/26968132.html Mon, 24 Aug 2026 16:06:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Grace+Therapeutics%2C+Inc.+++++++++++++/26968132.html si-local-file:///var/storage/secattach/20260824/26968132.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++Grace+Therapeutics%2C+Inc.+++++++++++++/26968132.html Mon, 24 Aug 2026 16:06:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+14++Filed+by%3A+Opaleye+Management+Inc./26947309.html si-local-file:///var/storage/secattach/20260819/26947309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+14++Filed+by%3A+Opaleye+Management+Inc./26947309.html Wed, 19 Aug 2026 07:45:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+14++Filed+by%3A+Opaleye+Management+Inc./26947309.html si-local-file:///var/storage/secattach/20260819/26947309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+14++Filed+by%3A+Opaleye+Management+Inc./26947309.html Wed, 19 Aug 2026 07:45:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932574.html si-local-file:///var/storage/secattach/20260814/26932574.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932574.html Fri, 14 Aug 2026 17:05:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932574.html si-local-file:///var/storage/secattach/20260814/26932574.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26932574.html Fri, 14 Aug 2026 17:05:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932178.html si-local-file:///var/storage/secattach/20260814/26932178.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932178.html Fri, 14 Aug 2026 16:49:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932178.html si-local-file:///var/storage/secattach/20260814/26932178.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Grace+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932178.html Fri, 14 Aug 2026 16:49:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+13/26916841.html si-local-file:///var/storage/secattach/20260813/26916841.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+13/26916841.html Thu, 13 Aug 2026 08:01:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+13/26916841.html si-local-file:///var/storage/secattach/20260813/26916841.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Grace+Therapeutics%2C+Inc.++For%3A+Aug+13/26916841.html Thu, 13 Aug 2026 08:01:00 -0400 GRCE O.07433357 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Press+Releases/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html <p align="justify">PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.</p> <p align="justify">“We continue to make progress on the requirements for resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “As previously disclosed, the U.S. Food and http://www.streetinsider.com/Globe+Newswire/Grace+Therapeutics+Announces+First+Quarter+2027+Financial+Results%2C+Provides+Business+Update/26916749.html Thu, 13 Aug 2026 08:00:00 -0400 A.50216777 GRCE O.07433357 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+30/26916510.html si-local-file:///var/storage/secattach/20260813/26916510.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+30/26916510.html Thu, 13 Aug 2026 07:31:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+30/26916510.html si-local-file:///var/storage/secattach/20260813/26916510.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Grace+Therapeutics%2C+Inc.++For%3A+Jun+30/26916510.html Thu, 13 Aug 2026 07:31:00 -0400 GRCE O.07433357 http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Grace+Therapeutics%2C+Inc.+++++++++++++/26900402.html si-local-file:///var/storage/secattach/20260811/26900402.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Grace+Therapeutics%2C+Inc.+++++++++++++/26900402.html Tue, 11 Aug 2026 06:01:00 -0400 GRCE O.07433357